Onartuzumab

Last updated
Onartuzumab
Monoclonal antibody
Type Fab fragment
Source Humanized (from mouse)
Target scatter factor receptor kinase
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C4422H6820N1168O1363S31
Molar mass 99147.88 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer. [1] [2] [3]

Onartuzumab was developed by Genentech, Inc. It is undergoing clinical trials. [4] [5] [6] [7]

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab" (PDF). American Medical Association.
  2. ↑ Padda S, Neal JW, Wakelee HA (December 2012). "MET inhibitors in combination with other therapies in non-small cell lung cancer". Transl Lung Cancer Res. 1 (4): 238–53. doi:10.3978/j.issn.2218-6751.2012.10.08. PMC   4367550 . PMID   25806189.
  3. ↑ Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F (May 2015). "Onartuzumab in lung cancer: the fall of Icarus?". Expert Rev Anticancer Ther. 15 (5): 487–9. doi: 10.1586/14737140.2015.1031219 . PMID   25818471.
  4. ↑ Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S (November 2013). "Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors". J Clin Pharmacol. 53 (11): 1103–11. doi:10.1002/jcph.148. PMID   23922054. S2CID   206059437.
  5. ↑ Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H (November 2012). "Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer". Clin Lung Cancer. 13 (6): 500–4. doi:10.1016/j.cllc.2012.05.009. PMID   23063071.
  6. ↑ Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC (November 2013). "Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer". J. Clin. Oncol. 31 (32): 4105–14. doi:10.1200/JCO.2012.47.4189. PMC   4878106 . PMID   24101053.
  7. ↑ Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T (June 2015). "Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer". Invest New Drugs. 33 (3): 632–40. doi:10.1007/s10637-015-0227-5. PMID   25777467. S2CID   20118425.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.